Adjuvant Therapy in Renal Cell Cancer

被引:0
作者
Jackson-Spence, Francesca [1 ]
Young, Matthew [1 ]
Jovaisaite, Agne [1 ]
Szabados, Bernadett [1 ]
Powles, Thomas [1 ]
机构
[1] Queen Mary Univ London, Barts Canc Inst, Dept Genitourinary Oncol, Charterhouse Sq, London EC1M 6BQ, England
关键词
Adjuvant; immune checkpoint inhibitors; anti-VEGF TKIs; post nephrectomy; renal cell carcinoma; DOUBLE-BLIND; HIGH-RISK; CARCINOMA; NEPHRECTOMY; SUNITINIB; PLACEBO; NIVOLUMAB; TRIALS;
D O I
10.3233/KCA-230013
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A number of adjuvant trials have attempted to improve outcomes for patients following nephrectomy for renal cell carcinoma (RCC). This was initially with cytokines and then Vascular Endothelial Growth Factor (VEGF) targeted therapies. More recently, a series of adjuvant immune checkpoint inhibitor (ICI) studies have been published. To date, only the KEYNOTE-564 study using adjuvant pembrolizumab has positive Disease-Free Survival (DFS) data with an acceptable toxicity profile. There are many negative ICI and anti-VEGF adjuvant trials, which raises uncertainty. Further randomised trials may be required but importantly biomarker studies are needed to identify those individuals who may benefit from adjuvant therapy.
引用
收藏
页码:17 / 22
页数:6
相关论文
共 50 条
  • [41] How to select targeted therapy in renal cell cancer
    Escudier, B.
    Albiges, L.
    Blesius, A.
    Loriot, Y.
    Massard, C.
    Fizazi, K.
    ANNALS OF ONCOLOGY, 2010, 21 : 59 - 62
  • [42] Adjuvant immunotherapy for renal cell carcinoma
    Sendur, Mehmet Ali Nahit
    LANCET ONCOLOGY, 2022, 23 (09) : 1110 - 1111
  • [43] Adjuvant Therapy for Renal Cell Carcinoma: Past, Present, and Future
    Pal, Sumanta K.
    Haas, Naomi B.
    ONCOLOGIST, 2014, 19 (08) : 851 - 859
  • [44] Adjuvant therapy for renal cell carcinoma in 2023: hopes and disappointments
    Ilya Tsimafeyeu
    Michael F. Basin
    Gennady Bratslavsky
    World Journal of Urology, 2023, 41 : 1855 - 1859
  • [45] The 2022 Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitor Therapy for Renal Cell Carcinoma
    Bedke, Jens
    Albiges, Laurence
    Capitanio, Umberto
    Giles, Rachel H.
    Hora, Milan
    Ljungberg, Borje
    Marconi, Lorenzo
    Klatte, Tobias
    Volpe, Alessandro
    Abu-Ghanem, Yasmin
    Dabestani, Saeed
    Fernandez-Pello, Sergio
    Hofmann, Fabian
    Kuusk, Teele
    Tahbaz, Rana
    Powles, Thomas
    Bex, Axel
    EUROPEAN UROLOGY, 2023, 83 (01) : 10 - +
  • [46] Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non - small cell lung cancer, and renal cell carcinoma
    Luke, Jason J.
    Long, Georgina V.
    Robert, Caroline
    Carlino, Matteo S.
    Choueiri, Toni K.
    Haas, Naomi B.
    O'Brien, Mary
    Paz-Ares, Luis
    Peters, Solange
    Powles, Thomas
    Leiby, Melanie A.
    Lin, Jianxin
    Zhao, Yujie
    Krepler, Clemens
    Perini, Rodolfo F.
    Pietanza, M. Catherine
    Samkari, Ayman
    Gruber, Todd
    Ibrahim, Nageatte
    Eggermont, Alexander M. M.
    EUROPEAN JOURNAL OF CANCER, 2024, 207
  • [47] Adjuvant and Neoadjuvant Therapy in Renal Cell Carcinoma
    Choueiri, Michel
    Tannir, Nizar
    Jonasch, Eric
    CURRENT CLINICAL PHARMACOLOGY, 2011, 6 (03): : 144 - 150
  • [48] The emerging role of targeted therapy in renal cell carcinoma (RCC): Is it time for a neoadjuvant or an adjuvant approach?
    Sciarra, Alessandro
    Cattarino, Susanna
    Salciccia, Stefano
    Alfarone, Andrea
    Gentilucci, Alessandro
    Parente, Ulderico
    Mariotti, Gianna
    Innocenzi, Michele
    Gentile, Vincenzo
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2012, 81 (02) : 151 - 162
  • [49] The Current State of Adjuvant Therapy Following Surgery for High-risk Renal Cell Carcinoma
    Ridyard, Douglas G.
    Buller, Dylan M.
    Ristau, Benjamin T.
    EUROPEAN UROLOGY FOCUS, 2019, 5 (06): : 935 - 938
  • [50] Neoadjuvant and adjuvant treatment of renal cell carcinoma
    Thillai, Kiruthikah
    Allan, Suzanne
    Powles, Thomas
    Rudman, Sarah
    Chowdhury, Simon
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (06) : 765 - 776